<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01916109</url>
  </required_header>
  <id_info>
    <org_study_id>10-103</org_study_id>
    <nct_id>NCT01916109</nct_id>
  </id_info>
  <brief_title>Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer</brief_title>
  <official_title>Phase II Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if using the combination of standard chemotherapy
      (gemcitabine and carboplatin) plus this new drug (panitumumab) can help to shrink the tumor
      before the patient undergoes surgery for bladder cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual
  </why_stopped>
  <start_date>August 2013</start_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic Complete Response Rate (&lt;pT0)</measure>
    <time_frame>1 year</time_frame>
    <description>The absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive four cycles of GCaP administered every 21 days. Panitumumab will be administered intravenously at a dose of 9mg/kg on day 1. Gemcitabine 1,000 mg/m2 on day 1 and 8 and carboplatin AUC 4.5 on day 1 will be administered intravenously on a 21-day cycle. A total of four cycles of therapy will be administered at 21-day intervals followed by radical cystectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Panitumumab</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical cystectomy</intervention_name>
    <arm_group_label>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed muscle invasive transitional cell carcinoma of the bladder at
             MSKCC (Note: urothelial carcinoma invading into the prostatic stroma with no
             histologic muscle invasion is allowed, provided the extent of disease is confirmed via
             imaging and/or EUA.)

          -  Clinical stage T2-T4a N0/X M0 disease.

          -  Medically appropriate candidate for radical cystectomy as per MSKCC attending urologic
             oncologist

          -  Karnofsky Performance Status ≥ 80%

          -  Age ≥ 18 years of age

          -  Required Initial Laboratory Values:

        Absolute neutrophil count ≥ 1500 cells/mm3

          -  Platelets ≥ 100,000 cells/mm3

          -  Hemoglobin ≥ 9.0g/dL

          -  Bilirubin ≤ 1.5 the upper limit of normal (ULN) for the institution

          -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN for the
             institution

          -  Alkaline phosphatase ≤ 2.5 x ULN for the institution

          -  Serum magnesium &gt; 1.4 mEq/L

          -  Serum creatinine ≤ 2.0 mg/dL

          -  Cisplatin ineligibility based on one or more of the following criteria:

        Estimated glomerular filtration rate (eGFR) 30-59 ml/min/1.73m2 using the CKD-EPI
        equation:(http://nephron.org/MDRD_GFR.cgi) :

        eGFR = 141 x min(Scr/k, 1)a x max(Scr/k, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159
        [if black] Scr is serum creatinine, k is 0.7 for females and 0.9 for males, a is -0.329 for
        females and -0.411 for males, min indicates the minimum of Scr/k or 1, and max indicates
        the maximum of Scr/k or 1.

          -  Grade 2 sensory neuropathy

          -  Grade 2 hearing loss

               -  Patients must provide a pretreatment saliva sample for genomic analysis.

        Exclusion Criteria:

          -  Prior systemic chemotherapy (prior intravesical therapy is allowed)

          -  Serious intercurrent medical or psychiatric illness.

          -  Prior radiation therapy to the bladder.

          -  Concomitant use of any other investigational drugs

          -  Any of the following within the 6 months prior to study drug administration:
             myocardial infarction, grade 2 or greater peripheral vascular disease, arterial
             thrombotic event, visceral arterial ischemia, cerebrovascular ischemia, transient
             ischemic attack, percutaneous transluminal angioplasty or stent, or unstable angina.

        Symptomatic and/or serious uncontrolled arrhythmia

          -  Symptomatic congestive heart failure (NYHA class III or IVI)

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan.

          -  History of any medical or psychiatric condition or laboratory abnormality that in the
             opinion of the investigator may increase the risk associated with the study
             participation or investigational product(s) administration or may interfere with the
             interpretation of the results.

          -  Major surgery requiring general anesthesia within 21 days or minor surgery within 14
             days of study enrollment. Subjects must have recovered from surgery related
             toxicities.

          -  Pulmonary embolism, deep vein thrombosis, or other significant venous event ≤ 8 weeks
             before enrollment

          -  Known allergy or hypersensitivity to any component of the study treatment(s)

          -  Active infection requiring systemic treatment or any uncontrolled infections ≤14 days
             prior to enrollment.

          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome
             (AIDS)-related illness.

          -  Concurrent treatment on another clinical trial. Supportive care trials, surgical
             clinical trials or non-treatment trials, e.g. QOL, are allowed.

          -  Ongoing treatment with therapeutic doses of warfarin (low dose warfarin up to 2 mg po
             daily for thromboembolic prophylaxis is allowed).

          -  Pregnancy or breast-feeding. Patients must be surgically sterile or be postmenopausal,
             or must agree to use effective contraception during the period of therapy and for two
             (2) months following the last dose of panitumumab. The definition of effective
             contraception will be based on the judgment of the principal investigator or a
             designated associate. Male patients must be surgically sterile or agree to use
             effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean Bajorin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center @ Suffolk</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering at Mercy Medical Center</name>
      <address>
        <city>Rockville Centre</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Cancer Center@Phelps</name>
      <address>
        <city>Sleepy Hollow</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 2, 2013</study_first_submitted>
  <study_first_submitted_qc>August 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2013</study_first_posted>
  <results_first_submitted>January 14, 2016</results_first_submitted>
  <results_first_submitted_qc>January 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2016</results_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gemcitabine</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Panitumumab</keyword>
  <keyword>(GCaP)</keyword>
  <keyword>radical cystectomy</keyword>
  <keyword>10-103</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
          <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
          <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pathologic Complete Response Rate (&lt;pT0)</title>
        <description>The absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
            <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
          </group>
        </group_list>
        <measure>
          <title>Pathologic Complete Response Rate (&lt;pT0)</title>
          <description>The absence of carcinoma (pT0 disease) and the absence of microscopic lymph node metastases (N0) on the final cystectomy specimen.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gemcitabine, Carboplatin, and Panitumumab (GCaP)</title>
          <description>Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTC-4.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Dean Bajorin</name_or_title>
      <organization>Memorial Sloan Kettering Cancer Center</organization>
      <phone>646-422-4333</phone>
      <email>bajorind@mskcc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

